A new Beginning..., page-2396

I often see a comparison of RAP's potential share price with other traditional medtech/biotech companies such as Resmed, etc.

However, this is primarily an ICT company and I think we should be comparing the potential share price to disrupting tech companies such as Afterpay. Its share price, after all, has gone from $1.00 in 2016 at listing to over $16.00 yesterday and was over $20 during the course of last year. It of course doesn't need the same regulatory approval as RAP requires so our road to such an increase in the share price may be a little longer!

Just a thought and my opinion